Get the Stockscreener App
27.99
1.67%
0.46
After Hours:
27.99
Alkermes Plc stock is traded at $27.99, with a volume of 1.08M.
It is up +1.67% in the last 24 hours and down -1.62% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.53
Open:
$27.43
24h Volume:
1.08M
Relative Volume:
0.63
Market Cap:
$4.70B
Revenue:
$1.51B
Net Income/Loss:
$288.72M
P/E Ratio:
22.57
EPS:
1.24
Net Cash Flow:
$327.15M
1W Performance:
-0.39%
1M Performance:
-1.62%
6M Performance:
+3.40%
1Y Performance:
-0.07%
1-Day Range:
$27.33
$28.07
1-Week Range:
$25.94
$28.27
52-Week Range:
$22.01
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Thrivent Financial for Lutherans Sells 70,398 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Short Interest Update - MarketBeat
Susquehanna Portfolio Strategies LLC Trims Stock Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Trading (ALKS) With Integrated Risk Controls - Stock Traders Daily
Ensign Peak Advisors Inc Decreases Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Wall Street SWOT: Alkermes stockNeuro-innovator's growth potential under scrutiny - Investing.com
Brokerages Set Alkermes plc (NASDAQ:ALKS) Target Price at $36.70 - MarketBeat
Dimensional Fund Advisors LP Purchases 371,039 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Substance Abuse Treatment Market Disclosing Recent Expansion, - openPR
Alkermes plc (NASDAQ:ALKS) Shares Sold by Canada Pension Plan Investment Board - MarketBeat
Schizophrenia Drugs Market SWOT Analysis by Leading Expert:AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Alkermes - openPR
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy - ShareCast
Alkermes plc (NASDAQ:ALKS) Shares Purchased by Affinity Asset Advisors LLC - MarketBeat
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy - StockTitan
ALK-Abelló (CPH:ALK B) pulls back 3.7% this week, but still delivers shareholders strong 20% CAGR over 5 years - Simply Wall St
Generalized Anxiety Disorder Global Market is Booming Across - openPR
Public Sector Pension Investment Board Has $8.97 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
KLAC (KLA Corp.) may reap gains as insiders became active recently - Knox Daily
Alkermes to Present Data on ALKS 2680 for Narcolepsy Type 2 and Idiopathic Hypersomnia - Sleep Review
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 - PR Newswire
Pacer Advisors Inc. Purchases 1,362,079 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Market Insights: Alaska Air Group Inc. (ALK)’s Notable Drop of -0.50, Closing at 39.56 - The Dwinnex
Here's Why Alkermes (ALKS) is a Strong Value Stock - Yahoo Finance
Brighton Jones LLC Has $7.21 Million Stock Holdings in Alaska Air Group, Inc. (NYSE:ALK) - MarketBeat
Zacks Research Weighs in on Alaska Air Group, Inc.’s Q3 2024 Earnings (NYSE:ALK) - Defense World
Zacks Research Weighs in on Alaska Air Group, Inc.'s Q3 2024 Earnings (NYSE:ALK) - MarketBeat
DekaBank Deutsche Girozentrale Makes New Investment in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference - The Malaysian Reserve
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference - StockTitan
Primecap Management Co. CA Sells 87,395 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Acquired by Victory Capital Management Inc. - Defense World
(ALKS) On The My Stocks Page - Stock Traders Daily
American Century Companies Inc. Buys 1,025,905 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Is Alkermes (NASDAQ:ALKS) A Risky Investment? - Simply Wall St
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Alkermes (NASDAQ:ALKS) Rating Reiterated by Cantor Fitzgerald - MarketBeat
Texas Permanent School Fund Corp Trims Stock Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Renaissance Technologies LLC Sells 403,320 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Bought by AGF Management Ltd. - MarketBeat
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program - PR Newswire
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program - StockTitan
LSV Asset Management Purchases 115,300 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Here's Why Alkermes (ALKS) is a Strong Growth Stock - MSN
Mizuho Remains Optimistic on Alkermes Amidst Competitive Narcolepsy Market - AskTraders
Rice Hall James & Associates LLC Raises Stock Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Nanotechnology Drug Delivery Market Detailed In New Research - openPR
Zacks Research Comments on Alkermes plc's Q1 2025 Earnings (NASDAQ:ALKS) - MarketBeat
Van ECK Associates Corp Invests $1.81 Million in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Here's Why Alkermes (ALKS) is a Strong Growth Stock - Yahoo Finance
Addiction Treatment Market 2024 Emerging Trends Industry - openPR
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):